

## Publications of HRU members in 2020 year

Averhoff F, Shadaker S, Gamkrelidze A, Kuchuloria T, Gvinjilia L, Getia V, Sergeenko D, Butsashvili M, Tsertsvadze T, Sharvadze L, Zarkua J, Skaggs B, Nasrullah M. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. *J Hepatol*. 2020 Apr;72(4):680-687. doi: 10.1016/j.jhep.2019.11.019. Epub 2019 Dec 4. PMID: 31811882; PMCID: PMC7418146.

Butsashvili M, Kamkamidze G, Kajaia M, Gvinjilia L, Kuchuloria T, Khonelidze I, Gogia M, Dolmazashvili E, Kerashvili V, Zakalashvili M, Shadaker S, Nasrullah M, Sonjelle S, Japaridze M, Averhoff F. Integration of hepatitis C treatment at harm reduction centers in Georgia-Findings from a patient satisfaction survey. *Int J Drug Policy*. 2020 Oct;84:102893. doi: 10.1016/j.drugpo.2020.102893. Epub 2020 Jul 31. PMID: 32739613; PMCID: PMC7738314.

Walker JG, Kuchuloria T, Sergeenko D, Fraser H, Lim AG, Shadaker S, Hagan L, Gamkrelidze A, Kvaratskhelia V, Gvinjilia L, Aladashvili M, Asatiani A, Baliashvili D, Butsashvili M, Chikovani I, Khonelidze I, Kirtadze I, Kuniholm MH, Otiashvili D, Sharvadze L, Stvilia K, Tsertsvadze T, Zakalashvili M, Hickman M, Martin NK, Morgan J, Nasrullah M, Averhoff F, Vickerman P. Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. *Lancet Glob Health*. 2020 Feb;8(2):e244-e253. doi: 10.1016/S2214-109X(19)30483-8. Epub 2019 Dec 18. PMID: 31864917; PMCID: PMC7025283.

Shadaker S, Nasrullah M, Gamkrelidze A, Ray J, Gvinjilia L, Kuchuloria T, Butsashvili M, Getia V, Metreveli D, Tsereteli M, Tsertsvadze T, Link-Gelles R, Millman AJ, Turdziladze A, Averhoff F. Screening and linkage to care for hepatitis C among inpatients in Georgia's national hospital screening program. *Prev Med*. 2020 Sep;138:106153. doi: 10.1016/j.ypmed.2020.106153. Epub 2020 May 27. PMID: 32473265; PMCID: PMC7440391.

Butsashvili M, Gvinjilia L, Kamkamidze G, Metreveli D, Dvali S, Rukhadze T, Gamkrelidze A, Nasrullah M, Shadaker S, Morgan J, Averhoff F. High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia. *BMC Res Notes*. 2020 Jul 11;13(1):332. doi: 10.1186/s13104-020-05173-4. PMID: 32653020; PMCID: PMC7353763.

Tsertsvadze T, Gamkrelidze A, Chkhartishvili N, Abutidze A, Sharvadze L, Kerashvili V, Butsashvili M, Metreveli D, Gvinjilia L, Shadaker S, Nasrullah M, Adamia E, Zeuzem S, Afdhal N, Arora S, Thornton K, Skaggs B, Kuchuloria T, Lagvilava M, Sergeenko D, Averhoff F. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018. *Clin Infect Dis*. 2020 Aug 22;71(5):1263-1268. doi: 10.1093/cid/ciz956. PMID: 31563938; PMCID: PMC7484896.

Tsertsvadze T, Gamkrelidze A, Nasrullah M, Sharvadze L, Morgan J, Shadaker S, Gvinjilia L, Butsashvili M, Metreveli D, Kerashvili V, Ezugbaia M, Chkhartishvili N, Abutidze A, Kvaratskhelia V, Averhoff F. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia. *BMC Infect Dis.* 2020 Jan 10;20(1):30. doi: 10.1186/s12879-019-4741-5. PMID: 31924172; PMCID: PMC6954615.